Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics reports news on its CNS oncology business, which combines precision diagnostics with targeted radiopharmaceutical development for central nervous system cancers. Recurring updates cover REYOBIQ™ (rhenium Re186 obisbemeda), a radiotherapeutic program for indications including leptomeningeal metastases and recurrent glioblastoma, as well as clinical and translational presentations, regulatory designations, manufacturing technology transfer and supply-chain partnerships.
The company’s news also covers the commercial expansion of CNSide®, including payer coverage, Medicare enrollment and reimbursement work for its cerebrospinal fluid assay platform. Corporate updates include leadership appointments, equity inducement grants under Nasdaq rules, financial results, capital actions and listing-compliance matters tied to its Nasdaq-traded common stock.
Plus Therapeutics (PSTV) reported its Q1 2020 financial results with a net loss of $1.1 million, or $0.28 per share, showing improvement from a $2.5 million loss in Q1 2019. Operating cash usage decreased to $1.5 million compared to $3.3 million last year. The company has secured a licensing agreement for rare cancer therapies, including Rhenium-186-chelated NanoLiposome for glioblastoma, with potential milestone payments totaling $136.5 million. Plus Therapeutics ended the quarter with $16.1 million in cash and emphasizes ongoing clinical trials and pipeline expansion.
Plus Therapeutics (PSTV) announced a live webinar, led by Dr. Andrew Brenner, on a new radiotherapy for recurrent glioblastoma scheduled for May 17, 2020. This initiative is part of the Musella Foundation Webinar Series and aims to educate patients and raise awareness during Brain Tumor Awareness Month. Plus Therapeutics recently licensed a radiolabeled nanoliposome drug portfolio, with its lead asset, Rhenium NanoLiposome (RNL™), supported by a $3.7 million NIH/NCI grant. The platform focuses on delivering high-dose radiation directly to brain tumors via advanced delivery techniques.
Plus Therapeutics (PSTV) announced the closing of a licensing agreement for rare cancer product candidates from NanoTx Therapeutics. The deal involves an upfront payment of $400,000 in cash and $300,000 in stock, with potential milestone payments totaling $136.5 million and royalties on U.S. and European sales. The lead asset, Rhenium-186-chelated NanoLiposome (RNL™), is under Phase 1 clinical trials for recurrent glioblastoma, aiming to deliver radiation doses significantly higher than traditional methods. Plus aims to address unmet medical needs in oncology with significant revenue opportunities.